MIRA PHARMACEUTICALS, INC. - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on December 5, 2025, by MIRA Pharmaceuticals, Inc., a Florida corporation trading on the Nasdaq Capital Market under the symbol MIRA. The filing addresses an update to the Company's At The Market (ATM) equity offering program.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial data disclosed relates to the equity offering program:
- Additional Offering Capacity: $15,241,591
- Previously Sold under Agreement: $7,034,658
- Underwriter: Rodman & Renshaw LLC
Material Changes
The primary material event is the increase in the maximum aggregate offering amount of Common Stock issuable under the Sales Agreement dated August 12, 2024 (amended September 24, 2024). The Company filed a prospectus supplement to authorize the sale of an additional $15,241,591 worth of shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard implications of an equity offering. The Company is identified as an emerging growth company.
Investor Verification Checklist
- Verify the total remaining capacity under the updated Sales Agreement with Rodman & Renshaw LLC.
- Review the filed Prospectus Supplement for specific terms regarding share issuance and pricing.
- Check recent 10-Q or 10-K filings for the Company's current cash position and burn rate to assess the necessity of this capital raise.
- Confirm the number of shares previously sold ($7,034,658) and the average price per share to understand dilution impact.